Citation

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RAJ, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP. New Engl. J. Med. 2016; 374(13): 1232-1242.

Copyright

(Copyright © 2016, Massachusetts Medical Society)

DOI

10.1056/NEJMoa1505409

PMID

unavailable

Abstract

Opioid-use disorder is a chronic relapsing condition that has serious public health consequences. Opioid dependence disproportionately affects U.S. criminal justice system populations, and relapse and overdose deaths occur at high rates after release from incarceration.1 Evidence-based opioid-agonist maintenance therapies for opioid dependence (methadone and buprenorphine) are effective in prison, jail, and community reentry (i.e., parole) settings2-5 but have historically been unavailable or discouraged among criminal justice clients.6-8 Extended-release naltrexone (Vivitrol, Alkermes), a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, was approved by the Food and Drug Administration in 2010 for the prevention of relapse to. . .

Language: en